Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment Specifical...
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment...
GENEVA, SWITZERLAND / ACCESSWIRE / February 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief " or the " Company ") announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt. Mr. Burckhardt has resigned to focus his time and effo...
Relief Therapeutics (RLFTF) affirms that its partner NeuroRx has initiated a phase 2/3 clinical trial investigating inhaled RLF-100 (aviptadil; Zyesami) for the treatment of severe COVID-19 in partnership with UCI Health of the University of California, Irvine.The objective of ...
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaboration and license agreement by June 30, 2021 GENEVA and NEWTON, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE)...
Relief Therapeutics (RLFTF) and Acer Therapeutics (ACER) have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001.ACER-001 (sodium phenylbutyrate) powder is a t...
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaboration and license agreement by June 30, 2021 GENEVA, SWITZERLAND, and NEWTON, MA / ACCESSWIRE / January 25, 2021 / R...
GENEVA, SWITZERLAND / ACCESSWIRE / January 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
NeuroRx, Relief Therapeutics ([[RLFTF]] +5.4%) and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a clinical trial participation agreement for the inclusion of Zyesami (RLF-100 aviptadil) in the I-SPY COVID-19 trial....
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial PR Newswire RADNOR, Pa. and GENEVA , Jan. 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding ...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...